Watch CGEM. Know when insiders buy.
One email the day a filing lands. Free.
CGEM
Cullinan Therapeutics, Inc.
21.31
−0.38 −1.75%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · shorts 42
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.4BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$204.7MNET CASH —52W 5.75 – 22.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$57.3M | −$53.7M | — | — | −$38.2M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$53.7M | −$49.7M | — | — | −$46M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$55.3M | −$50.7M | — | — | −$38.1M | $11K | −$38.1M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$55.6M | −$50.6M | — | — | −$36.9M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$75.8M | −$70.1M | — | — | −$57.6M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$55M | −$48.5M | — | — | −$43.2M | — | — | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$55M | −$47.6M | — | — | −$36.6M | $0 | −$36.6M | Mar 10 |
| Q3 2024 · Sep 30 | — | — | — | −$48.9M | −$40.6M | — | -0.69 | −$34.1M | $0 | −$34.1M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$50M | −$42M | — | -0.75 | −$36.3M | $0 | −$36.3M | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$43M | −$37.1M | — | -0.86 | −$38.2M | $0 | −$38.2M | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$45.5M | −$23.8M | — | -0.54 | −$18.1M | $0 | −$18.1M | Feb 27 |
| Q3 2023 · Sep 30 | — | — | — | −$45.2M | −$39.2M | — | -0.91 | −$34.1M | $0 | −$34.1M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$241.6M | −$219.9M | — | — | −$175.8M | $49K | −$175.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$196.9M | −$167.4M | — | — | −$145.3M | $0 | −$145.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$191.1M | −$153.2M | — | -3.69 | −$134.3M | $208K | −$134.5M | — | — |
| FY2022 · to Dec 31 | $0 | — | $144.6M | $111.2M | — | 2.38 | −$126.7M | $1.1M | −$127.8M | — | — |
| FY2021 · to Dec 31 | $18.9M | — | −$68M | −$65.6M | -346.1% | -1.52 | −$43.4M | $0 | −$43.4M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$60.3M | −$51.8M | — | -2.60 | −$29.8M | $10K | −$29.8M | $6.6M | — |
Every number comes from Cullinan Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.